Togawa et al. demonstrated that in rats with DSS-induced colitis the oral administration of bLf decreased disease severity in a dose-dependent manner, as reflected by the improvement in clinical disease activity index, white blood cell count and hemoglobin concentration, macroscopic and histological scores and reduced myeloperoxidase (MPO) activity, used as a marker for neutrophil infiltration [238]. This evidence concerns the gene MPO and colitis.